Table 2.
Frequencies and ORs of CHOLESTASIS information if three drugs were used in different combinations in ALL group.
| Drug combination | NC+all | Nall | FreqC/all | OR | lnOR | Error | NP | NC+P | FreqC/P | 
|---|---|---|---|---|---|---|---|---|---|
| AMXC+OMPZ+LSPZ | 31 | 445 | 6.97% | 40.59 | 3.70 | 0.37 | 23 | 23 | 100.00% | 
| AMXC+OMPZ-LSPZ | 170 | 6793 | 2.50% | 14.02 | 2.64 | 0.15 | 21 | 2 | 9.52% | 
| AMXC+LSPZ-OMPZ | 31 | 2864 | 1.08% | 5.93 | 1.78 | 0.35 | 5 | 0 | 0.00% | 
| LSPZ+OMPZ-AMXC | 27 | 4731 | 0.57% | 3.11 | 1.13 | 0.38 | 6 | 0 | 0.00% | 
| AMXC-LSPZ-OMPZ | 1279 | 56346 | 2.27% | 13.49 | 2.60 | 0.06 | 542 | 4 | 0.74% | 
| OMPZ-LSPZ-AMXC | 974 | 250340 | 0.39% | 2.18 | 0.78 | 0.06 | 574 | 3 | 0.52% | 
| LSPZ-OMPZ-AMXC | 342 | 94558 | 0.36% | 1.98 | 0.69 | 0.11 | 158 | 1 | 0.63% | 
NC+all, Number of records with CHOLESTASIS and the drug combination in the “ALL” group; Nall, Number of records containing the drug combination in the “ALL” group; FreqC/all, Frequency of CHOLESTASIS after taking the drug combination in the “ALL” group; NP, Number of drug combination in the “pregnancy” group; NC+P, Number of records with CHOLESTASIS and the drug combination in the “pregnancy” group; FreqC/P, Frequency of CHOLESTASIS after taking the drug combination in the “pregnancy” group.